Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma.
Aberrant methylation is a main mechanism of tumor suppressor gene inactivation in carcinogenesis. In this study, the methylation status of RASSF1A, p16, MLH1, MSH2 and ERalpha was investigated in 84 primary soft tissue sarcomas (STSs), including 22 liposarcomas, 18 malignant fibrous histiocytomas (MFHs), 18 leiomyosarcomas, 6 rhabdomyosarcomas, 6 neurogenic sarcomas and several other sarcoma entities. RASSF1A hypermethylation was detected in 17 of 84 (20%) STSs; however, methylation was more frequent in leiomyosarcomas (39%) compared to MFHs (6%; p < 0.015) and liposarcomas (18%). The p16 CpG island was methylated in 22 out of 82 (27%) cases. In 7 out of 81 (9%) STS samples, the promoter of MLH1 was methylated and in liposarcoma the methylation frequency was higher (14%). For MSH2, no hypermethylation was detected. Methylation of ERalpha was detected in 48 of 63 (76%) STSs, but also in 4 of 8 (50%) normal tissue samples. Furthermore, we analyzed mutational activation of K-ras and BRAF. In 4 out of 84 (5%) of STSs, a substitution at codon 599 of BRAF was found; however, no alteration of K-ras was detected. In an univariate Cox proportional-hazards regression model, we found that the risk of a tumor-related death for STS patients with methylated RASSF1A was significantly increased (RR = 2.9; p = 0.037). In summary, our data indicate that inactivation of RASSF1A is a common event in STS, especially in leiomyosarcoma. Thus, the methylation status of cancer-related genes was distinct in different STS and methylation of RASSF1A promoter can serve as prognostic marker in STSs.
Seidel
Claudia
C
Autonomous Work Group Tumor Genetics of the Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle/Saale, Germany.
Bartel
Frank
F
Rastetter
Matthias
M
Bluemke
Karen
K
Wurl
Peter
P
Taubert
Helge
H
Dammann
Reinhard
R
D000328:Adult; D019175:DNA Methylation; D018219:Histiocytoma, Benign Fibrous / Q000235:genetics / Q000473:pathology; D006801:Humans; D007890:Leiomyosarcoma / Q000235:genetics* / Q000473:pathology*; D008080:Liposarcoma / Q000235:genetics / Q000473:pathology; D011379:Prognosis; D011401:Promoter Regions, Genetic; D012509:Sarcoma / Q000235:genetics* / Q000473:pathology*; D016019:Survival Analysis; D025521:Tumor Suppressor Proteins / Q000235:genetics* / Q000378:metabolism*
C411762:RASSF1 protein, human; D025521:Tumor Suppressor Proteins